155 CORRELATION OF KNEE CARTILAGE THICKNESS CHANGE AT 1 YEAR WITH CLINICAL OUTCOME CHANGES AT 1 AND 3 YEARS: DATA FROM THE OSTEOARTHRITIS INITIATIVE

Objective.To evaluate whether features of radiographic hand osteoarthritis (OA) are associated with quantitative magnetic resonance imaging (MRI)-defined knee cartilage thickness, radiographic knee OA, and 1-year structural progression.Methods.A total of 765 participants in Osteoarthritis Initiative (OAI; 455 women, mean age 62.5 yrs, SD 9.4) obtained hand radiographs (at baseline), knee radiographs (baseline and Year 1), and knee MRI (baseline and Year 1). Hand radiographs were scored for presence of osteophytes and joint space narrowing (JSN). Knee radiographs were scored according to the Kellgren-Lawrence (KL) scale. Cartilage thickness in the medial and lateral femorotibial compartments was measured quantitatively from coronal FLASHwe images. We examined the cross-sectional and longitudinal associations between features of hand OA (total osteophyte and JSN scores) and knee cartilage thickness, 1-year knee cartilage thinning (above smallest detectable change), presence of knee OA (KL grade ≥ 3), and progression of knee OA (KL change ≥ 1) by linear and logistic regression. Both hand OA features were included in a multivariate model (if p ≤ 0.25) adjusted for age, sex, and body mass index (BMI).Results.Hand JSN was associated with reduced knee cartilage thickness (ß = −0.02, 95% CI −0.03, −0.01) in the medial femorotibial compartment, while hand osteophytes were associated with the presence of radiographic knee OA (OR 1.10, 95% CI 1.03–1.18; multivariate models) with both hand OA features as independent variables adjusted for age, sex, and BMI). Radiographic features of hand OA were not associated with 1-year cartilage thinning or radiographic knee OA progression.Conclusion.Our results support a systemic OA susceptibility and possibly different mechanisms for osteophyte formation and cartilage thinning.

Download Full-text

Does radiographic status of the contralateral knee impact cartilage thickness change in radiographically normal knees – data from the osteoarthritis initiative

Osteoarthritis and Cartilage ◽

10.1016/j.joca.2018.02.838 ◽

2018 ◽

Vol 26 ◽

pp. S435-S436

Author(s):

S. Mascheck ◽

W. Wirth ◽

G.N. Duda ◽

L. Sharma ◽

F. Eckstein

Keyword(s):

Cartilage Thickness ◽

Thickness Change ◽

Contralateral Knee ◽

Osteoarthritis Initiative

Download Full-text

Intra-articular sprifermin reduces cartilage loss in addition to increasing cartilage gain independent of location in the femorotibial joint: post-hoc analysis of a randomised, placebo-controlled phase II clinical trial

Annals of the Rheumatic Diseases ◽

10.1136/annrheumdis-2019-216453 ◽

2020 ◽

Vol 79 (4) ◽

pp. 525-528 ◽

Cited By ~ 3

Author(s):

Felix Eckstein ◽

Jeffrey L Kraines ◽

Aida Aydemir ◽

Wolfgang Wirth ◽

Susanne Maschek ◽

...

Keyword(s):

Phase Ii ◽

Healthy Subjects ◽

Cartilage Thickness ◽

Cartilage Loss ◽

Thickness Change ◽

Post Hoc Analysis ◽

Registration Number ◽

Osteoarthritis Initiative ◽

Post Hoc ◽

Femorotibial Joint

ObjectivesIn the phase II FGF-18 Osteoarthritis Randomized Trial with Administration of Repeated Doses (FORWARD) study, sprifermin demonstrated cartilage modification in the total femorotibial joint and in both femorotibial compartments by MRI in patients with knee osteoarthritis. Here, we evaluate whether sprifermin reduces cartilage loss and increases cartilage thickness, independent of location.MethodsPatients were randomised 1:1:1:1:1 to three once-weekly intra-articular injections of 30 µg sprifermin every 6 months (q6mo); 30 µg sprifermin every 12 months (q12mo); 100 µg sprifermin q6mo; 100 µg sprifermin q12mo; or placebo. Post-hoc analysis using thinning/thickening scores and ordered values evaluated femorotibial cartilage thickness change from baseline to 24 months independent of location. Changes were indirectly compared with those of Osteoarthritis Initiative healthy subjects.ResultsThinning scores were significantly lower for sprifermin 100 µg q6mo versus placebo (mean (95% CI) difference: 334 µm (114 to 554)), with a cartilage thinning score similar to healthy subjects. Thickening scores were significantly greater for sprifermin 100 µg q6mo, 100 µg q12mo and 30 µg q6mo versus placebo (mean (95% CI) difference: 425 µm (267 to 584); 450 µm (305 to 594) and 139 µm (19 to 259), respectively) and more than doubled versus healthy subjects.ConclusionsSprifermin increases cartilage thickness, and substantially reduces cartilage loss, expanding FORWARD primary results.Trial registration numberNCT01919164.

Download Full-text